Back to Search Results

Dual Enkephalinase Inhibitors and Their Role in Chronic Pain Management.

Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA. wsouther@bidmc.harvard.edu. Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA. Department of Anesthesiology, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA. Department of Anesthesiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Current pain and headache reports. 2021;(5):29
Full text from:

Other resources

Abstract

PURPOSE OF REVIEW Dual enkephalinase inhibitors (DENKIs) are pain medications that indirectly activate opioid receptors and can be used as an alternative to traditional opioids. Understanding the physiology of enkephalins and their inhibitors and the pharmacology of these drugs will allow for proper clinical application for chronic pain patients in the future. RECENT FINDINGS DENKIs can be used as an alternative mode of analgesia for patients suffering from chronic pain by preventing the degradation of endogenous opioid ligands. By inhibiting the two major enkephalin-degrading enzymes (neprilysin and aminopeptidase N), DENKIs can provide analgesia with less adverse effects than nonendogenous opioids. The purpose of this paper is to review the current literature investigating DENKIs and explore their contribution to chronic pain management.

Methodological quality

Publication Type : Review

Metadata